Skip to main content
. 2021 Jun 18;6:86. doi: 10.1038/s41541-021-00348-x

Fig. 3. In vivo vaccination with PRGN-2012 induced immunity against an E6 epitope shared between HPV6 and HPV11.

Fig. 3

a Experimental design of peripheral T lymphocytes from wild-type C57BL/6 mice vaccinated with PRGN-2012 assessed for HPV antigen-specific immune responses. b Photomicrographs of representative ELISpot wells demonstrating responses to HPV6 and 11 overlapping 15-mer peptide pools as well as synthesized minimal peptides following in vivo vaccination with PRGN-2012 but not empty GC46. c Quantification of IFNγ spots in vaccinated male (n = 3) and female (n = 3) mice. d Quantification of IFNγ spots in an independent validation in vivo vaccination experiment in female wild-type C57BL/6 mice (n = 5). e Quantification (left) and representative flow cytometry dot plots (right) of CD8+ T-lymphocyte IFNγ production following assessment of HPV antigen-specific T-lymphocyte responses from mice vaccinated with PRGN-2012 or empty GC46, measured by intracellular flow cytometry (n = 6/group). Dot plots show gated live, CD3+CD8+ T lymphocytes from mice vaccinated with PRGN-2012. Similar experimental results were observed in three independent experiments. APC antigen presenting cell, OP overlapping peptides. **p < 0.01; Student’s t test.